Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(18), С. 6057 - 6057
Опубликована: Сен. 19, 2023
There
are
no
published
studies
on
the
prevalence
of
non-alcoholic
fatty
liver
disease
(NAFLD)
in
patients
with
atopic
dermatitis
(AD).
To
estimate
NAFLD
(assessed
via
ultrasonography)
adults
moderate-to-severe
AD.
We
performed
a
retrospective,
cross-sectional,
observational
study
including
adult
affected
by
AD,
chronic
plaque
psoriasis,
or
previous
diagnosis
thin
melanoma
situ
(considered
as
control
group)
who
attended
Verona
University
Hospital
between
January
2022
and
April
2023.
Fatty
was
assessed
ultrasonography.
A
total
144
466
99
were
included.
The
rates
ultrasound-detected
among
melanoma,
those
psoriasis
23.2%
(23
out
99),
24.1%
(36
144),
49.8%
(228
466),
respectively
(p
<
0.01).
Logistic
regression
analysis
revealed
that
being
male
sex,
higher
age,
body
mass
index,
independently
associated
NAFLD,
whereas
AD
not.
Our
findings
show
comparable
to
melanoma.
It
is
plausible
hypothesize
Th2-type
inflammation
typically
characterizing
not
risk
factor
for
NAFLD.
Patients
but
should
be
screened
other
metabolic
comorbidities.
Metabolites,
Год журнала:
2024,
Номер
14(7), С. 366 - 366
Опубликована: Июнь 28, 2024
Nonalcoholic
fatty
liver
disease
(NAFLD)
poses
an
emerging
threat
topublic
health.
steatohepatitis
(NASH)
is
reported
to
be
the
most
rapidly
rising
cause
of
hepatocellular
carcinoma
in
western
world.
Recently,
a
new
term
has
been
proposed:
metabolic
dysfunction-associated
steatotic
(MASLD).
The
introduction
this
terminology
sparked
debate
about
interchangeability
these
terms.
pathogenesis
NAFLD/MASLD
thought
multifactorial,
involving
both
genetic
and
environmental
factors.
Among
factors,
alterations
gut
microbiota
dysbiosis
have
recently
garnered
significant
attention.
In
context,
review
will
further
discuss
gut-liver
axis,
which
refers
bidirectional
interaction
between
human
liver.
Additionally,
therapeutic
potential
probiotics,
particularly
next-generation
probiotics
genetically
engineered
bacteria,
explored.
Moreover,
role
prebiotics,
synbiotics,
postbiotics,
phages
as
well
fecal
transplantation
analyzed.
Particularly
for
lean
patients
with
NAFLD/MASLD,
who
limited
treatment
options,
approaches
that
modify
diversity
composition
may
hold
promise.
However,
due
ongoing
safety
concerns
modulate
microbiota,
large-scale
studies
are
necessary
better
assess
their
efficacy
treating
NAFLD/MASLD.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 6, 2023
The
treatment
of
cancer
was
revolutionized
within
the
last
two
decades
by
utilizing
mechanism
immune
system
against
malignant
tissue
in
so-called
immunotherapy.
Two
main
developments
boosted
immunotherapy:
1)
use
checkpoint
inhibitors,
which
are
characterized
a
relatively
high
response
rate
mainly
solid
tumors;
however,
at
cost
serious
side
effects,
and
2)
chimeric
antigen
receptor
(CAR)-T
cells,
were
shown
to
be
very
efficient
hematologic
malignancies,
but
failed
show
clinical
effectiveness
tumors
until
now.
In
addition,
active
immunization
individual
is
emerging,
first
products
have
reached
approval.
These
new
options
cost-intensive
not
financially
compensated
health
insurance
many
countries.
Hence,
strategies
must
developed
make
immunotherapy
affordable
improve
cost-benefit
ratio.
this
review,
we
discuss
following
strategies:
leverage
antigenicity
“cold
tumors”
with
reagents,
microbiome-based
as
markers
or
therapeutics,
3)
apply
measures
that
adoptive
cell
therapy
(ACT)
cheaper,
e.g.,
off-the-shelf
products,
4)
immunotherapies
offer
cheaper
platforms,
such
RNA-
peptide-based
vaccines
shared
common
antigens
instead
highly
personal
antigens,
5)
small
set
predictive
biomarkers
“sequence
everything”
approach,
6)
explore
immunohistochemistry
may
direct
therapies.
Advanced Healthcare Materials,
Год журнала:
2024,
Номер
13(21)
Опубликована: Янв. 20, 2024
The
human
gut
extracts
nutrients
from
the
diet
while
forming
largest
barrier
against
outer
environment.
In
addition,
actively
maintains
homeostasis
through
intricate
interactions
with
microbes,
immune
system,
enteric
nervous
and
other
organs.
These
influence
digestive
health
and,
furthermore,
play
crucial
roles
in
systemic
disease.
Given
its
primary
role
absorbing
metabolizing
orally
administered
drugs,
there
is
significant
interest
development
of
preclinical
vitro
model
systems
that
can
accurately
emulate
intestine
vivo.
A
gut-on-a-chip
system
holds
great
potential
as
a
testing
screening
platform
because
ability
to
physiological
aspects
vivo
tissues
expandability
incorporate
combine
This
review
aims
identify
key
features
need
be
incorporated
build
more
accurate
models
highlights
recent
progress
competing
technologies
toward
building
physiologically
relevant
systems.
Furthermore,
various
efforts
construct
multi-organ
gut,
called
gut-organ-axis-on-a-chip
models,
are
discussed.
relevance
provide
valuable
platforms
for
bridging
gap
between
clinical
studies.
Food & Function,
Год журнала:
2024,
Номер
15(19), С. 9632 - 9661
Опубликована: Янв. 1, 2024
Metabolic
syndrome
(MetS)
is
a
disease
condition
incorporating
the
abnormal
accumulation
of
various
metabolic
components,
including
obesity,
insulin
resistance
and
glucose
tolerance,
hypertension,
atherosclerosis,
or
dyslipidemia.
Nutrients,
Год журнала:
2024,
Номер
16(18), С. 3189 - 3189
Опубликована: Сен. 20, 2024
Background:
This
study
investigates
the
hypolipidemic
effects
of
a
mixed
extract
Salvia
miltiorrhiza
and
Paeonia
lactiflora
(USCP119)
in
HFD-fed
hamsters
vitro
cellular
models.
Methods:
Over
an
8-week
period,
were
assigned
to
one
six
groups:
normal
diet,
HFD
control,
with
50
mg/kg
USCP119,
100
USCP119
twice
daily
(BID),
omega-3
fatty
acids.
Key
outcomes
assessed
included
body
weight,
serum
triglycerides
(TG),
total
cholesterol
(TC),
liver
hepatic
TG
levels,
epididymal
fat.
In
models,
impact
on
lipid
accumulation
adipogenic
markers
was
evaluated.
Results:
treatment
at
BID
resulted
lowest
weight
gain
(15.5%)
most
significant
reductions
levels
compared
control.
The
dose
also
led
substantial
TC
notable
decreases
low-density
lipoprotein
cholesterol.
once
reduced
but
less
effective
than
higher
doses.
non-toxic
up
400
µg/mL
effectively
accumulation,
modulated
markers,
enhanced
AMPK
signaling,
improving
metabolism
insulin
sensitivity.
Conclusions:
All
treatments
demonstrated
effectiveness
managing
hyperlipidemia
related
metabolic
disorders,
variations
depending
dosage.
ability
reduce
fat
improve
profiles,
enhance
sensitivity
highlights
its
potential
as
valuable
dietary
supplement
for
addressing
high-fat
diet-induced
disturbances.
